Sugi Predict

Sugi Predict / Compounds / SCHEMBL1098601

SCHEMBL1098601

SCHEMBL1098601

COC(=O)CCCS(=O)(=O)Cl

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.58
▸ CA12 O43570 4/20 0.47
▸ CA14 Q9ULX7 4/20 0.47
▸ LMNA P02545 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CA7 P43166 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ CA2 P00918 1/20 0.41
▸ KAT2B Q92831 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ GLA P06280 1/20 0.37
▸ EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19402824 0.94 TSHR (0.56) TSHRCA12CA14LMNAALDH1A1
SCHEMBL30200780 0.92 TSHR (0.54) TSHRCA12CA14LMNAALDH1A1
SCHEMBL1403393 0.92 TSHR (0.54) TSHRCA12CA14LMNAALDH1A1
SCHEMBL1403149 0.92 TSHR (0.54) TSHRCA12CA14LMNAALDH1A1
SCHEMBL770916 0.86 TSHR (0.55) TSHRCA12CA14LMNAALDH1A1
Hydrochloric Acid SCHEMBL28548757 0.84 TSHR (0.52) TSHRCA12CA14LMNAALDH1A1
SCHEMBL17188350 0.80 TSHR (0.61) TSHRCA12CA14LMNAALDH1A1
SCHEMBL4968131 0.80 TSHR (0.61) TSHRCA12CA14LMNAALDH1A1
SCHEMBL19402733 0.79 CYP1A2 (0.53) TSHRALDH1A1KAT2BKMT2A
SCHEMBL416459 0.78 TSHR (0.58) TSHRCA12CA14LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE INCYTE CORPORATION 2023-12-14 — — US disclosed
US-11713317-B2 Tricyclic heterocyclic compounds as sting activators INCYTE CORPORATION (US) 2023-08-01 — — US disclosed
US-11596692-B1 PD-L1/STING conjugates and methods of use INCYTE CORPORATION (US) 2023-03-07 — — US disclosed
EP-3802534-B1 TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS INCYTE CORP (US) 2022-07-13 — — EP disclosed
US-20220073509-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION 2022-03-10 — — US disclosed
US-10947227-B2 Tricyclic heterocyclic compounds as sting activators INCYTE CORPORATION (US) 2021-03-16 — — US disclosed
EP-3434671-A1 SULTAM COMPOUND AND APPLICATION METHOD THEREOF Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2019-01-30 — — EP disclosed
US-20180319812-A1 HETEROCYCLIC COMPOUND ACTION MEDICAL TECHNOLOGIES, LLC 2018-11-08 — — US disclosed
US-10053468-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-08-21 — — US disclosed
WO-2017162157-A1 SULTAM COMPOUND AND APPLICATION METHOD THEREOF 正大天晴药业集团股份有限公司 2017-09-28 — — WO disclosed
WO-2012122340-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-13 — — WO disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 — — US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 — — US disclosed
WO-2011140160-A1 BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-10 — — WO disclosed
WO-2011140161-A1 BENZOFURANYL ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-10 — — WO disclosed
CN-101801949-A Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2010-08-11 — — CN disclosed
EP-2183239-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-05-12 — — EP disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 — — US disclosed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 — — WO disclosed
WO-2004056798-A1 PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2004-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053468-B2 Heterocyclic compound RORC, RORB, RORA TSHR 1505/4885CA12 1747/4885CA14 2343/4885
US-20180319812-A1 HETEROCYCLIC COMPOUND RORC, RORB, RORA TSHR 1505/4885CA12 1747/4885CA14 2343/4885
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TSHR 1373/4885CA12 2056/4885CA14 3050/4885
US-20220073509-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS STING1, MAVS, IRF3 TSHR 4092/4885CA12 4749/4885CA14 4696/4885
US-11596692-B1 PD-L1/STING conjugates and methods of use STING1, PDCD1LG2, CD274 TSHR 1533/4885CA12 3397/4885CA14 3945/4885
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE STING1, PDCD1LG2, CD274 TSHR 1533/4885CA12 3397/4885CA14 3945/4885
US-11713317-B2 Tricyclic heterocyclic compounds as sting activators STING1, MAVS, IRF3 TSHR 4092/4885CA12 4749/4885CA14 4696/4885
US-10947227-B2 Tricyclic heterocyclic compounds as sting activators STING1, MAVS, IRF3 TSHR 4092/4885CA12 4749/4885CA14 4696/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TSHR 1373/4885CA12 2056/4885CA14 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.